• Aliases: OSI-774, CP 358774
    • Reversibly binds to the intracellular catalytic domain of EGFR
    • FDA approved for NSCLC and pancreatic cancer
    • Recommended dose: 150 mg once daily (NSCLC) and 100 mg once daily (pancreatic cancer) on empty stomach 1 hour before or 2 hours after meals. Avoid proton pump inhibitors and grapefruit juice.
    • Half-life: 36 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Rash (acne vulgaris, pruritus), diarrhea, paronychia (hair and nail changes), fatigue, weakness, back pain, cough, dyspnea, conjunctivitis
    • Clinical pearls: Severity of acne-form rash can be minimized with the use , and doxycycline, Encourage smoking cessation prior to start because smoking can make the drug less effective.
    Other topics in Targeted and Immunotherapy Agents